TOKYO, Japan and CAMBRIDGE, Massachusetts, February 20 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it has officially opened a new representative office in Japan and has appointed Soh Fujiwara as Managing Director for Japanese operations.
Shire's new office in Shinkujuku Ward, Tokyo, will serve as the base for preparations for the future commercialization of its pipeline products in Japan, the second largest biopharmaceutical market in the world. Shire currently focuses its business on the areas of attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) and human genetic therapies, and markets products in pharmaceutical markets worldwide.
"The unique regulatory, clinical and cultural characteristics of the Japanese market require an early investment in infrastructure to maximize the potential in this strategically important region," said Sylvie Gregoire, President of Shire Human Genetic Therapies, the business unit focusing on treating rare diseases. "Through the opening of this new office, we have taken a significant step toward increasing our presence in this market. Soh Fujiwara joins Shire at a critical time in our global expansion, and we look forward to working closely with him and his team to build an infrastructure that will enable us to bring additional therapies to Japanese patients."
Mr. Fujiwara joins Shire as Managing Director for Japanese operations
after spending more than 20 years in the pharmaceutical industry. During his
career, Mr. Fujiwara has spent a significant amount of time working on the
development of products for rare diseases. In his new role, Mr. Fujiwara will
oversee the implementation and development of clinical and regulatory
strategies for the commercializat
|SOURCE Shire Plc|
Copyright©2009 PR Newswire.
All rights reserved